Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

146.85
+2.621.82%
Pre-market: 146.55-0.3000-0.20%04:01 EDT
Volume:5.10M
Turnover:749.91M
Market Cap:182.19B
PE:-56.16
High:148.60
Open:145.28
Low:144.85
Close:144.23
52wk High:157.29
52wk Low:114.02
Shares:1.24B
Float Shares:1.24B
Volume Ratio:1.03
T/O Rate:0.41%
Dividend:3.22
Dividend Rate:2.19%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.40
PE(LYR):21.66

Loading ...

Gilead announces agreement with PAHO for lenacapavir access

TIPRANKS
·
Sep 15

Gilead: Explores Opportunities with Brazilian Health Ministry to Advance Ministry’s Goal of Enabling Local Production of Lenacapavir

THOMSON REUTERS
·
Sep 15

Gilead: Agreement Establishes Regional Pathway Through Pan American Health Organization's Regional Revolving Funds

THOMSON REUTERS
·
Sep 15

Gilead: Co & Paho Announce Partnership to Accelerate Access to Twice-Yearly Lenacapavir for Hiv Prevention Across Latin America & Caribbean

THOMSON REUTERS
·
Sep 15

Gilead, PAHO Agree on HIV Prevention Drug Access in Latin America, Caribbean

Reuters
·
Sep 15

Gilead: to Continue Exploring Opportunities to Work with Paho to Support Country Readiness & Scale-up of Long-Acting Hiv Prevention Access

THOMSON REUTERS
·
Sep 15

Gilead Exec Says Weekly Oral Hiv Prevention Drug Expected to Launch in First Quarter of 2027 - Conf Call

THOMSON REUTERS
·
Sep 15

Gilead Exec Says Hiv Market Growth Should Normalize to 2%-3% Within Next Couple of Quarters - Conf Call

THOMSON REUTERS
·
Sep 15

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

Moderna Inc. Stock Rallies 5.4%, Outperforms Peers

Dow Jones
·
Sep 12

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

TIPRANKS
·
Sep 11

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Sep 09

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for Hsv Helicase-Primase Inhibitor Program

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Sep 09

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Sep 09

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS
·
Sep 09